We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $163M
1-Year Est. Return 240.43%
This Fund
S&P 500
This Quarter Est. Return
-21.89%
1 Year Est. Return
+240.43%
3 Year Est. Return
+409.28%
5 Year Est. Return
+142.09%
10 Year Est. Return
+4,071.98%
AUM
$77.3M
AUM Growth
-$25.8M
Cap. Flow
+$5.46M
Cap. Flow %
7.06%
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$23.8M
2
CTNM
Contineum Therapeutics
CTNM
+$14.8M

Top Sells

Rank Stock Value
1
PASG icon
Passage Bio
PASG
+$1.14M
2
ALGS icon
Aligos Therapeutics
ALGS
+$607K
3
ADVM
Adverum Biotechnologies
ADVM
+$9

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$5.12B
$26.9M 34.84%
498,558
– –
CTNM
2
Contineum Therapeutics
CTNM
$558M
$16.2M 20.92%
+918,163
New +$14.8M
SKYE icon
3
Skye Bioscience
SKYE
$9.03M
$16.1M 20.81%
+250,963
New +$23.8M
RPTX
4
DELISTED
Repare Therapeutics
RPTX
$8.73M 11.3%
2,646,657
– –
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$3.48M 4.5%
506,821
-1
-0% -$9
PASG icon
6
Passage Bio
PASG
$16.1M
$3.2M 4.14%
201,321
-46,667
-19% -$1.14M
GRTS
7
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.2M 2.85%
3,561,150
– –
ALGS icon
8
Aligos Therapeutics
ALGS
$32.6M
$510K 0.66%
58,317
-34,498
-37% -$607K

Similar funds

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GF
Gimbal Financial Carmel, Indiana $163M AUM
ACM
Arrington Capital Management Miami, Florida $163M AUM
KFS
Krane Financial Solutions Calabasas, California $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
GCM
Generation Capital Management Pittsford, New York $163M AUM 42.22% 1-Year Est. Return

Versant Venture Management's Q2 2024 Portfolio in Review

As of Q2 2024, Versant Venture Management held 9 positions worth $77.3M, down 25% from $103M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $5.46M of net new capital in Q2 2024, opening 2 new positions. Its largest new stake was Skye Bioscience: 250,963 shares worth $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 70% a quarter earlier.

On the sell side, the largest reduction was Passage Bio, an estimated $1.14M trimmed.

  • Versant Venture Management's largest Q2 2024 buy was Skye Bioscience: 250,963 shares worth $16.1M.
  • Versant Venture Management's biggest Q2 2024 reduction was Passage Bio, cutting an estimated $1.14M.
  • Versant Venture Management's ten largest holdings make up 100% of its $77.3M portfolio in Q2 2024.
  • Versant Venture Management opened 2 new positions and closed 1 in Q2 2024.
  • Versant Venture Management's portfolio value fell 25% quarter-over-quarter to $77.3M.

Based on Versant Venture Management's 13F filing for Q2 2024, filed 7 Aug 2024.